Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04576702 · ClinicalTrials.gov registry record · Phase 2
Safety and Immunogenicity of an MF59-Adjuvanted Influenza Vaccine in Older Adults
A Phase 2 study, sponsored by Seqirus.
- Completed
- Registry status
- Phase 2
- Development phase
- 471
- Enrollment target
NCT04576702: Completed Phase 2 study, sponsored by Seqirus.
NCT04576702 is a Phase 2 study that has completed, run by Seqirus. The registered enrollment target is 471 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (254% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04576702, a Phase 2 study, has completed, sponsored by Seqirus.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 471 participants
- Enrollment target
Study Summary
This Phase 2, randomized, observer-blind, active controlled clinical study is evaluating the safety and immunogenicity of the investigational MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine. Approximately 480 subjects are to be randomized into 1 of 4 possible treatment groups (investigational Influenza Vaccine or licensed Quadrivalent Influenza Vaccine comparators) at 120 participants per group. Every participant will receive an influenza vaccine injection on Day 1 and will be followed up for approximately 6 months following injection. The primary immunogenicity analysis is based on Day 29 serum.
Interventions
- BIOLOGICAL Investigational aIIV4c
- BIOLOGICAL IIV4c
- BIOLOGICAL aIIV4
- BIOLOGICAL RIV4
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 471 participants |
| Start Date | 2020-10-08 |
| Est. Completion | 2021-05-24 |
| Phase | Phase 2 |
What the finished NCT04576702 record still lists
NCT04576702 is an interventional study that assigns participants to a tested intervention. The registered 471 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (254% higher).
The record links to 0 conditions, and to 4 interventions - of which Investigational aIIV4c is the first listed.
NCT04576702 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04576702 about?
NCT04576702 is a clinical study titled "Safety and Immunogenicity of an MF59-Adjuvanted Influenza Vaccine in Older Adults". This Phase 2, randomized, observer-blind, active controlled clinical study is evaluating the safety and immunogenicity of the investigational MF59-Adjuvanted Quadrivalent Subunit Inactivated Influenza Vaccine. Approximately 480 subjects are to be randomized into 1 of 4 possible treatment groups (inv...
What is the current status of trial NCT04576702?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 471 participants. The study started on 2020-10-08. Estimated completion is 2021-05-24.
What interventions are being tested in trial NCT04576702?
The interventions under investigation include: Investigational aIIV4c (BIOLOGICAL), IIV4c (BIOLOGICAL), aIIV4 (BIOLOGICAL), RIV4 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04576702?
This trial is sponsored by Seqirus, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04576702's enrollment target sits among peer trials
471 78th of 2000 higher than 1,923 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03010150 · 471 participants
Blood Tests and Questionnaires in Studying Adherence to Preventative Swallowing Exercises in Participants With Metastatic Head and Neck Cancer
- NCT05201404 · 471 participants · Phase 3
Namodenoson in the Treatment of Advanced Hepatocellular Carcinoma in Patients With Child-Pugh Class B7 Cirrhosis
- NCT06375083 · 472 participants · Phase 2
Computerized Cognitive Behavioral Therapies for Suicide Prevention and Depression
- NCT06947187 · 472 participants · NA
Vaccine Confidence and Infodemic in Southeast Asia's Nusantara Sociocultural Sphere
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI